nodes	percent_of_prediction	percent_of_DWPC	metapath
Bortezomib—CYP1A1—head and neck cancer	0.444	1	CbGaD
Bortezomib—CYP2D6—Hydroxyurea—head and neck cancer	0.0401	0.308	CbGbCtD
Bortezomib—CYP2C8—Fluorouracil—head and neck cancer	0.0241	0.185	CbGbCtD
Bortezomib—CYP1A2—Fluorouracil—head and neck cancer	0.0186	0.143	CbGbCtD
Bortezomib—CYP2C9—Fluorouracil—head and neck cancer	0.0168	0.129	CbGbCtD
Bortezomib—CYP2D6—Vinblastine—head and neck cancer	0.0142	0.109	CbGbCtD
Bortezomib—CYP3A4—Vinblastine—head and neck cancer	0.00904	0.0694	CbGbCtD
Bortezomib—CYP3A4—Docetaxel—head and neck cancer	0.00745	0.0572	CbGbCtD
Bortezomib—PSMD1—hair follicle—head and neck cancer	0.00385	0.0424	CbGeAlD
Bortezomib—PSMA1—mouth—head and neck cancer	0.0036	0.0396	CbGeAlD
Bortezomib—PSMD2—hair follicle—head and neck cancer	0.00341	0.0375	CbGeAlD
Bortezomib—PSMB5—hair follicle—head and neck cancer	0.003	0.0329	CbGeAlD
Bortezomib—PSMB1—hair follicle—head and neck cancer	0.00262	0.0288	CbGeAlD
Bortezomib—PSMB2—hair follicle—head and neck cancer	0.00255	0.0281	CbGeAlD
Bortezomib—CTSG—connective tissue—head and neck cancer	0.0023	0.0253	CbGeAlD
Bortezomib—SLC31A1—hair follicle—head and neck cancer	0.00221	0.0243	CbGeAlD
Bortezomib—PSMA1—connective tissue—head and neck cancer	0.00221	0.0243	CbGeAlD
Bortezomib—PSMD1—parotid gland—head and neck cancer	0.0021	0.0231	CbGeAlD
Bortezomib—PSMA1—epithelium—head and neck cancer	0.00209	0.023	CbGeAlD
Bortezomib—PSMB8—Vinorelbine—Vinblastine—head and neck cancer	0.00204	0.539	CbGdCrCtD
Bortezomib—PSMD1—saliva-secreting gland—head and neck cancer	0.00202	0.0222	CbGeAlD
Bortezomib—CTSG—trachea—head and neck cancer	0.00193	0.0212	CbGeAlD
Bortezomib—PSMD2—parotid gland—head and neck cancer	0.00186	0.0205	CbGeAlD
Bortezomib—PSMB8—parotid gland—head and neck cancer	0.00185	0.0204	CbGeAlD
Bortezomib—PSMD2—saliva-secreting gland—head and neck cancer	0.00179	0.0196	CbGeAlD
Bortezomib—PSMB8—saliva-secreting gland—head and neck cancer	0.00177	0.0195	CbGeAlD
Bortezomib—PSMB8—Vincristine—Vinblastine—head and neck cancer	0.00174	0.461	CbGdCrCtD
Bortezomib—CTSG—lymphoid tissue—head and neck cancer	0.00168	0.0185	CbGeAlD
Bortezomib—PSMB5—parotid gland—head and neck cancer	0.00164	0.018	CbGeAlD
Bortezomib—PSMA1—lymphoid tissue—head and neck cancer	0.00161	0.0177	CbGeAlD
Bortezomib—PSMB5—saliva-secreting gland—head and neck cancer	0.00157	0.0172	CbGeAlD
Bortezomib—PSMD1—trachea—head and neck cancer	0.00155	0.0171	CbGeAlD
Bortezomib—PSMA1—thyroid gland—head and neck cancer	0.00147	0.0161	CbGeAlD
Bortezomib—PSMB1—parotid gland—head and neck cancer	0.00143	0.0157	CbGeAlD
Bortezomib—PSMB2—parotid gland—head and neck cancer	0.0014	0.0153	CbGeAlD
Bortezomib—PSMD2—trachea—head and neck cancer	0.00138	0.0151	CbGeAlD
Bortezomib—PSMB1—saliva-secreting gland—head and neck cancer	0.00137	0.0151	CbGeAlD
Bortezomib—PSMB8—trachea—head and neck cancer	0.00137	0.0151	CbGeAlD
Bortezomib—PSMB2—saliva-secreting gland—head and neck cancer	0.00134	0.0147	CbGeAlD
Bortezomib—PSMA1—head—head and neck cancer	0.0013	0.0143	CbGeAlD
Bortezomib—PSMD1—thyroid gland—head and neck cancer	0.00123	0.0135	CbGeAlD
Bortezomib—PSMB2—connective tissue—head and neck cancer	0.00123	0.0135	CbGeAlD
Bortezomib—PSMB5—trachea—head and neck cancer	0.00121	0.0133	CbGeAlD
Bortezomib—SLC31A1—parotid gland—head and neck cancer	0.00121	0.0133	CbGeAlD
Bortezomib—PSMD2—lymphoid tissue—head and neck cancer	0.0012	0.0132	CbGeAlD
Bortezomib—SLC31A1—saliva-secreting gland—head and neck cancer	0.00116	0.0127	CbGeAlD
Bortezomib—PSMD2—thyroid gland—head and neck cancer	0.00109	0.012	CbGeAlD
Bortezomib—PSMB8—thyroid gland—head and neck cancer	0.00108	0.0119	CbGeAlD
Bortezomib—PSMB1—trachea—head and neck cancer	0.00106	0.0116	CbGeAlD
Bortezomib—PSMB2—trachea—head and neck cancer	0.00103	0.0113	CbGeAlD
Bortezomib—PSMD2—head—head and neck cancer	0.000967	0.0106	CbGeAlD
Bortezomib—PSMB5—thyroid gland—head and neck cancer	0.000957	0.0105	CbGeAlD
Bortezomib—CTSG—lymph node—head and neck cancer	0.000948	0.0104	CbGeAlD
Bortezomib—PSMB1—lymphoid tissue—head and neck cancer	0.000921	0.0101	CbGeAlD
Bortezomib—PSMA1—lymph node—head and neck cancer	0.00091	0.01	CbGeAlD
Bortezomib—PSMB2—lymphoid tissue—head and neck cancer	0.000898	0.00988	CbGeAlD
Bortezomib—SLC31A1—trachea—head and neck cancer	0.000893	0.00982	CbGeAlD
Bortezomib—PSMB1—thyroid gland—head and neck cancer	0.000836	0.00919	CbGeAlD
Bortezomib—PSMB2—thyroid gland—head and neck cancer	0.000816	0.00897	CbGeAlD
Bortezomib—PSMD1—lymph node—head and neck cancer	0.000764	0.0084	CbGeAlD
Bortezomib—PSMB1—head—head and neck cancer	0.000742	0.00816	CbGeAlD
Bortezomib—PSMB2—head—head and neck cancer	0.000724	0.00796	CbGeAlD
Bortezomib—SLC31A1—thyroid gland—head and neck cancer	0.000706	0.00777	CbGeAlD
Bortezomib—PSMD2—lymph node—head and neck cancer	0.000677	0.00744	CbGeAlD
Bortezomib—PSMB8—lymph node—head and neck cancer	0.000673	0.0074	CbGeAlD
Bortezomib—SLC31A1—head—head and neck cancer	0.000627	0.00689	CbGeAlD
Bortezomib—PSMB5—lymph node—head and neck cancer	0.000594	0.00653	CbGeAlD
Bortezomib—CYP1A1—mouth—head and neck cancer	0.00059	0.00648	CbGeAlD
Bortezomib—PSMB1—lymph node—head and neck cancer	0.000519	0.00571	CbGeAlD
Bortezomib—PSMB2—lymph node—head and neck cancer	0.000507	0.00557	CbGeAlD
Bortezomib—SLC31A1—lymph node—head and neck cancer	0.000439	0.00483	CbGeAlD
Bortezomib—CYP1A1—parotid gland—head and neck cancer	0.000411	0.00451	CbGeAlD
Bortezomib—CYP1A1—epithelium—head and neck cancer	0.000343	0.00377	CbGeAlD
Bortezomib—PTGS1—connective tissue—head and neck cancer	0.000317	0.00349	CbGeAlD
Bortezomib—Gastrointestinal haemorrhage—Fluorouracil—head and neck cancer	0.000304	0.0017	CcSEcCtD
Bortezomib—Osteoarthritis—Fluorouracil—head and neck cancer	0.000304	0.0017	CcSEcCtD
Bortezomib—CYP1A1—trachea—head and neck cancer	0.000303	0.00334	CbGeAlD
Bortezomib—Pulmonary embolism—Docetaxel—head and neck cancer	0.000303	0.00169	CcSEcCtD
Bortezomib—Hepatocellular injury—Docetaxel—head and neck cancer	0.000303	0.00169	CcSEcCtD
Bortezomib—PTGS1—epithelium—head and neck cancer	0.000301	0.00331	CbGeAlD
Bortezomib—Injection site reaction—Docetaxel—head and neck cancer	0.000301	0.00168	CcSEcCtD
Bortezomib—Haemoglobin—Hydroxyurea—head and neck cancer	0.000294	0.00164	CcSEcCtD
Bortezomib—Haemorrhage—Hydroxyurea—head and neck cancer	0.000293	0.00163	CcSEcCtD
Bortezomib—Hallucination—Hydroxyurea—head and neck cancer	0.000291	0.00162	CcSEcCtD
Bortezomib—Colitis—Docetaxel—head and neck cancer	0.000291	0.00162	CcSEcCtD
Bortezomib—Irritability—Fluorouracil—head and neck cancer	0.00029	0.00162	CcSEcCtD
Bortezomib—Cardiac arrest—Fluorouracil—head and neck cancer	0.000289	0.00161	CcSEcCtD
Bortezomib—Candida infection—Docetaxel—head and neck cancer	0.000289	0.00161	CcSEcCtD
Bortezomib—Fluid retention—Docetaxel—head and neck cancer	0.000287	0.0016	CcSEcCtD
Bortezomib—Ataxia—Fluorouracil—head and neck cancer	0.000286	0.0016	CcSEcCtD
Bortezomib—Neuropathy—Docetaxel—head and neck cancer	0.000284	0.00158	CcSEcCtD
Bortezomib—Dry skin—Fluorouracil—head and neck cancer	0.000279	0.00156	CcSEcCtD
Bortezomib—Oesophagitis—Docetaxel—head and neck cancer	0.000277	0.00154	CcSEcCtD
Bortezomib—Neoplasm—Docetaxel—head and neck cancer	0.000274	0.00153	CcSEcCtD
Bortezomib—Nasopharyngitis—Fluorouracil—head and neck cancer	0.000272	0.00152	CcSEcCtD
Bortezomib—Pulmonary oedema—Docetaxel—head and neck cancer	0.000269	0.0015	CcSEcCtD
Bortezomib—Muscular weakness—Fluorouracil—head and neck cancer	0.000268	0.0015	CcSEcCtD
Bortezomib—PTGS1—trachea—head and neck cancer	0.000266	0.00293	CbGeAlD
Bortezomib—Angiopathy—Hydroxyurea—head and neck cancer	0.000265	0.00148	CcSEcCtD
Bortezomib—Dysphagia—Fluorouracil—head and neck cancer	0.000263	0.00147	CcSEcCtD
Bortezomib—Sepsis—Docetaxel—head and neck cancer	0.000263	0.00146	CcSEcCtD
Bortezomib—Chills—Hydroxyurea—head and neck cancer	0.000262	0.00146	CcSEcCtD
Bortezomib—Ill-defined disorder—Vinblastine—head and neck cancer	0.000259	0.00144	CcSEcCtD
Bortezomib—Anaemia—Vinblastine—head and neck cancer	0.000258	0.00144	CcSEcCtD
Bortezomib—Angina pectoris—Fluorouracil—head and neck cancer	0.000256	0.00143	CcSEcCtD
Bortezomib—Phlebitis—Docetaxel—head and neck cancer	0.000255	0.00142	CcSEcCtD
Bortezomib—Erythema—Hydroxyurea—head and neck cancer	0.000255	0.00142	CcSEcCtD
Bortezomib—Thrombophlebitis—Docetaxel—head and neck cancer	0.000254	0.00142	CcSEcCtD
Bortezomib—Malaise—Vinblastine—head and neck cancer	0.000252	0.0014	CcSEcCtD
Bortezomib—Vertigo—Vinblastine—head and neck cancer	0.000251	0.0014	CcSEcCtD
Bortezomib—Leukopenia—Vinblastine—head and neck cancer	0.00025	0.00139	CcSEcCtD
Bortezomib—Pancytopenia—Fluorouracil—head and neck cancer	0.00025	0.00139	CcSEcCtD
Bortezomib—Deafness—Docetaxel—head and neck cancer	0.000246	0.00137	CcSEcCtD
Bortezomib—Upper respiratory tract infection—Fluorouracil—head and neck cancer	0.000244	0.00136	CcSEcCtD
Bortezomib—Hepatic failure—Docetaxel—head and neck cancer	0.000244	0.00136	CcSEcCtD
Bortezomib—CYP1A2—thyroid gland—head and neck cancer	0.000243	0.00267	CbGeAlD
Bortezomib—Cardiac failure congestive—Docetaxel—head and neck cancer	0.000242	0.00135	CcSEcCtD
Bortezomib—Convulsion—Vinblastine—head and neck cancer	0.000242	0.00135	CcSEcCtD
Bortezomib—Hypertension—Vinblastine—head and neck cancer	0.000241	0.00134	CcSEcCtD
Bortezomib—Photosensitivity reaction—Fluorouracil—head and neck cancer	0.00024	0.00134	CcSEcCtD
Bortezomib—CYP1A1—thyroid gland—head and neck cancer	0.00024	0.00264	CbGeAlD
Bortezomib—Ill-defined disorder—Hydroxyurea—head and neck cancer	0.000236	0.00132	CcSEcCtD
Bortezomib—Pneumonia—Fluorouracil—head and neck cancer	0.000236	0.00132	CcSEcCtD
Bortezomib—Anaemia—Hydroxyurea—head and neck cancer	0.000235	0.00131	CcSEcCtD
Bortezomib—Discomfort—Vinblastine—head and neck cancer	0.000235	0.00131	CcSEcCtD
Bortezomib—Infestation NOS—Fluorouracil—head and neck cancer	0.000235	0.00131	CcSEcCtD
Bortezomib—Infestation—Fluorouracil—head and neck cancer	0.000235	0.00131	CcSEcCtD
Bortezomib—Atrial fibrillation—Docetaxel—head and neck cancer	0.000232	0.00129	CcSEcCtD
Bortezomib—Acute coronary syndrome—Fluorouracil—head and neck cancer	0.000231	0.00129	CcSEcCtD
Bortezomib—Renal impairment—Docetaxel—head and neck cancer	0.000231	0.00129	CcSEcCtD
Bortezomib—Myocardial infarction—Fluorouracil—head and neck cancer	0.00023	0.00128	CcSEcCtD
Bortezomib—Neuropathy peripheral—Fluorouracil—head and neck cancer	0.00023	0.00128	CcSEcCtD
Bortezomib—Dermatitis bullous—Docetaxel—head and neck cancer	0.00023	0.00128	CcSEcCtD
Bortezomib—Malaise—Hydroxyurea—head and neck cancer	0.00023	0.00128	CcSEcCtD
Bortezomib—Stomatitis—Fluorouracil—head and neck cancer	0.000229	0.00127	CcSEcCtD
Bortezomib—Conjunctivitis—Fluorouracil—head and neck cancer	0.000228	0.00127	CcSEcCtD
Bortezomib—Urinary tract infection—Fluorouracil—head and neck cancer	0.000228	0.00127	CcSEcCtD
Bortezomib—Leukopenia—Hydroxyurea—head and neck cancer	0.000228	0.00127	CcSEcCtD
Bortezomib—Cardiac failure—Docetaxel—head and neck cancer	0.000225	0.00126	CcSEcCtD
Bortezomib—Lethargy—Docetaxel—head and neck cancer	0.000224	0.00125	CcSEcCtD
Bortezomib—Thrombocytopenia—Vinblastine—head and neck cancer	0.000223	0.00124	CcSEcCtD
Bortezomib—Epistaxis—Fluorouracil—head and neck cancer	0.000221	0.00123	CcSEcCtD
Bortezomib—Convulsion—Hydroxyurea—head and neck cancer	0.000221	0.00123	CcSEcCtD
Bortezomib—Hyponatraemia—Docetaxel—head and neck cancer	0.000221	0.00123	CcSEcCtD
Bortezomib—Sinusitis—Fluorouracil—head and neck cancer	0.00022	0.00123	CcSEcCtD
Bortezomib—Gastrointestinal haemorrhage—Docetaxel—head and neck cancer	0.00022	0.00123	CcSEcCtD
Bortezomib—Pain in extremity—Docetaxel—head and neck cancer	0.00022	0.00123	CcSEcCtD
Bortezomib—Anorexia—Vinblastine—head and neck cancer	0.000217	0.00121	CcSEcCtD
Bortezomib—Migraine—Docetaxel—head and neck cancer	0.000216	0.00121	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—head and neck cancer	0.000215	0.0012	CcSEcCtD
Bortezomib—Discomfort—Hydroxyurea—head and neck cancer	0.000214	0.00119	CcSEcCtD
Bortezomib—CYP1A1—head—head and neck cancer	0.000213	0.00234	CbGeAlD
Bortezomib—Haemoglobin—Fluorouracil—head and neck cancer	0.000212	0.00118	CcSEcCtD
Bortezomib—PTGS1—thyroid gland—head and neck cancer	0.000211	0.00232	CbGeAlD
Bortezomib—Haemorrhage—Fluorouracil—head and neck cancer	0.000211	0.00117	CcSEcCtD
Bortezomib—Hypoaesthesia—Fluorouracil—head and neck cancer	0.000209	0.00117	CcSEcCtD
Bortezomib—Oedema—Hydroxyurea—head and neck cancer	0.000208	0.00116	CcSEcCtD
Bortezomib—Ataxia—Docetaxel—head and neck cancer	0.000207	0.00115	CcSEcCtD
Bortezomib—Infection—Hydroxyurea—head and neck cancer	0.000206	0.00115	CcSEcCtD
Bortezomib—Paraesthesia—Vinblastine—head and neck cancer	0.000205	0.00114	CcSEcCtD
Bortezomib—Dehydration—Docetaxel—head and neck cancer	0.000204	0.00114	CcSEcCtD
Bortezomib—Nervous system disorder—Hydroxyurea—head and neck cancer	0.000204	0.00114	CcSEcCtD
Bortezomib—Thrombocytopenia—Hydroxyurea—head and neck cancer	0.000203	0.00113	CcSEcCtD
Bortezomib—Skin disorder—Hydroxyurea—head and neck cancer	0.000202	0.00113	CcSEcCtD
Bortezomib—Dry skin—Docetaxel—head and neck cancer	0.000201	0.00112	CcSEcCtD
Bortezomib—Orthostatic hypotension—Docetaxel—head and neck cancer	0.000201	0.00112	CcSEcCtD
Bortezomib—Abdominal pain upper—Docetaxel—head and neck cancer	0.000201	0.00112	CcSEcCtD
Bortezomib—Breast disorder—Docetaxel—head and neck cancer	0.000199	0.00111	CcSEcCtD
Bortezomib—Anorexia—Hydroxyurea—head and neck cancer	0.000198	0.0011	CcSEcCtD
Bortezomib—Decreased appetite—Vinblastine—head and neck cancer	0.000198	0.0011	CcSEcCtD
Bortezomib—Toxic epidermal necrolysis—Docetaxel—head and neck cancer	0.000198	0.0011	CcSEcCtD
Bortezomib—Cramp muscle—Docetaxel—head and neck cancer	0.000198	0.0011	CcSEcCtD
Bortezomib—Nasopharyngitis—Docetaxel—head and neck cancer	0.000196	0.0011	CcSEcCtD
Bortezomib—Pain—Vinblastine—head and neck cancer	0.000195	0.00109	CcSEcCtD
Bortezomib—Constipation—Vinblastine—head and neck cancer	0.000195	0.00109	CcSEcCtD
Bortezomib—Dysphagia—Docetaxel—head and neck cancer	0.00019	0.00106	CcSEcCtD
Bortezomib—Arrhythmia—Fluorouracil—head and neck cancer	0.000188	0.00105	CcSEcCtD
Bortezomib—Feeling abnormal—Vinblastine—head and neck cancer	0.000188	0.00105	CcSEcCtD
Bortezomib—PTGS1—head—head and neck cancer	0.000187	0.00206	CbGeAlD
Bortezomib—Bronchospasm—Docetaxel—head and neck cancer	0.000187	0.00104	CcSEcCtD
Bortezomib—Gastrointestinal pain—Vinblastine—head and neck cancer	0.000186	0.00104	CcSEcCtD
Bortezomib—Dyspnoea—Hydroxyurea—head and neck cancer	0.000185	0.00103	CcSEcCtD
Bortezomib—Angina pectoris—Docetaxel—head and neck cancer	0.000185	0.00103	CcSEcCtD
Bortezomib—Erythema—Fluorouracil—head and neck cancer	0.000183	0.00102	CcSEcCtD
Bortezomib—Dyspepsia—Hydroxyurea—head and neck cancer	0.000183	0.00102	CcSEcCtD
Bortezomib—Decreased appetite—Hydroxyurea—head and neck cancer	0.000181	0.00101	CcSEcCtD
Bortezomib—Pancytopenia—Docetaxel—head and neck cancer	0.00018	0.00101	CcSEcCtD
Bortezomib—Abdominal pain—Vinblastine—head and neck cancer	0.00018	0.001	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Hydroxyurea—head and neck cancer	0.000179	0.001	CcSEcCtD
Bortezomib—Fatigue—Hydroxyurea—head and neck cancer	0.000179	0.000999	CcSEcCtD
Bortezomib—Constipation—Hydroxyurea—head and neck cancer	0.000178	0.000991	CcSEcCtD
Bortezomib—Pain—Hydroxyurea—head and neck cancer	0.000178	0.000991	CcSEcCtD
Bortezomib—Neutropenia—Docetaxel—head and neck cancer	0.000178	0.00099	CcSEcCtD
Bortezomib—Weight increased—Docetaxel—head and neck cancer	0.000173	0.000964	CcSEcCtD
Bortezomib—Vision blurred—Fluorouracil—head and neck cancer	0.000173	0.000963	CcSEcCtD
Bortezomib—Weight decreased—Docetaxel—head and neck cancer	0.000172	0.000958	CcSEcCtD
Bortezomib—Feeling abnormal—Hydroxyurea—head and neck cancer	0.000171	0.000955	CcSEcCtD
Bortezomib—Pneumonia—Docetaxel—head and neck cancer	0.00017	0.00095	CcSEcCtD
Bortezomib—Anaemia—Fluorouracil—head and neck cancer	0.000169	0.000945	CcSEcCtD
Bortezomib—Infestation NOS—Docetaxel—head and neck cancer	0.000169	0.000944	CcSEcCtD
Bortezomib—Infestation—Docetaxel—head and neck cancer	0.000169	0.000944	CcSEcCtD
Bortezomib—Hypersensitivity—Vinblastine—head and neck cancer	0.000168	0.000936	CcSEcCtD
Bortezomib—Stevens-Johnson syndrome—Docetaxel—head and neck cancer	0.000168	0.000936	CcSEcCtD
Bortezomib—Acute coronary syndrome—Docetaxel—head and neck cancer	0.000167	0.000931	CcSEcCtD
Bortezomib—Renal failure—Docetaxel—head and neck cancer	0.000166	0.000928	CcSEcCtD
Bortezomib—Neuropathy peripheral—Docetaxel—head and neck cancer	0.000166	0.000925	CcSEcCtD
Bortezomib—Myocardial infarction—Docetaxel—head and neck cancer	0.000166	0.000925	CcSEcCtD
Bortezomib—Stomatitis—Docetaxel—head and neck cancer	0.000165	0.00092	CcSEcCtD
Bortezomib—Conjunctivitis—Docetaxel—head and neck cancer	0.000165	0.000918	CcSEcCtD
Bortezomib—Body temperature increased—Hydroxyurea—head and neck cancer	0.000164	0.000916	CcSEcCtD
Bortezomib—Leukopenia—Fluorouracil—head and neck cancer	0.000164	0.000915	CcSEcCtD
Bortezomib—Asthenia—Vinblastine—head and neck cancer	0.000163	0.000912	CcSEcCtD
Bortezomib—Hepatobiliary disease—Docetaxel—head and neck cancer	0.00016	0.000893	CcSEcCtD
Bortezomib—Epistaxis—Docetaxel—head and neck cancer	0.00016	0.00089	CcSEcCtD
Bortezomib—Convulsion—Fluorouracil—head and neck cancer	0.000159	0.000886	CcSEcCtD
Bortezomib—Chest pain—Fluorouracil—head and neck cancer	0.000156	0.00087	CcSEcCtD
Bortezomib—Myalgia—Fluorouracil—head and neck cancer	0.000156	0.00087	CcSEcCtD
Bortezomib—Diarrhoea—Vinblastine—head and neck cancer	0.000156	0.000869	CcSEcCtD
Bortezomib—Discomfort—Fluorouracil—head and neck cancer	0.000154	0.00086	CcSEcCtD
Bortezomib—CYP2D6—head—head and neck cancer	0.000154	0.00169	CbGeAlD
Bortezomib—Hypersensitivity—Hydroxyurea—head and neck cancer	0.000153	0.000854	CcSEcCtD
Bortezomib—Haemoglobin—Docetaxel—head and neck cancer	0.000153	0.000852	CcSEcCtD
Bortezomib—Haemorrhage—Docetaxel—head and neck cancer	0.000152	0.000847	CcSEcCtD
Bortezomib—Hepatitis—Docetaxel—head and neck cancer	0.000152	0.000847	CcSEcCtD
Bortezomib—Hypoaesthesia—Docetaxel—head and neck cancer	0.000151	0.000843	CcSEcCtD
Bortezomib—Confusional state—Fluorouracil—head and neck cancer	0.000151	0.000841	CcSEcCtD
Bortezomib—Dizziness—Vinblastine—head and neck cancer	0.000151	0.00084	CcSEcCtD
Bortezomib—Urinary tract disorder—Docetaxel—head and neck cancer	0.00015	0.000837	CcSEcCtD
Bortezomib—Oedema peripheral—Docetaxel—head and neck cancer	0.00015	0.000835	CcSEcCtD
Bortezomib—Oedema—Fluorouracil—head and neck cancer	0.00015	0.000834	CcSEcCtD
Bortezomib—Anaphylactic shock—Fluorouracil—head and neck cancer	0.00015	0.000834	CcSEcCtD
Bortezomib—Connective tissue disorder—Docetaxel—head and neck cancer	0.000149	0.000833	CcSEcCtD
Bortezomib—Asthenia—Hydroxyurea—head and neck cancer	0.000149	0.000832	CcSEcCtD
Bortezomib—CYP1A1—lymph node—head and neck cancer	0.000149	0.00164	CbGeAlD
Bortezomib—Urethral disorder—Docetaxel—head and neck cancer	0.000149	0.000831	CcSEcCtD
Bortezomib—Infection—Fluorouracil—head and neck cancer	0.000149	0.000829	CcSEcCtD
Bortezomib—Nervous system disorder—Fluorouracil—head and neck cancer	0.000147	0.000818	CcSEcCtD
Bortezomib—Thrombocytopenia—Fluorouracil—head and neck cancer	0.000146	0.000817	CcSEcCtD
Bortezomib—Visual impairment—Docetaxel—head and neck cancer	0.000146	0.000817	CcSEcCtD
Bortezomib—Tachycardia—Fluorouracil—head and neck cancer	0.000146	0.000814	CcSEcCtD
Bortezomib—Vomiting—Vinblastine—head and neck cancer	0.000145	0.000808	CcSEcCtD
Bortezomib—Erythema multiforme—Docetaxel—head and neck cancer	0.000144	0.000801	CcSEcCtD
Bortezomib—Headache—Vinblastine—head and neck cancer	0.000143	0.000796	CcSEcCtD
Bortezomib—Anorexia—Fluorouracil—head and neck cancer	0.000143	0.000795	CcSEcCtD
Bortezomib—Diarrhoea—Hydroxyurea—head and neck cancer	0.000142	0.000793	CcSEcCtD
Bortezomib—Eye disorder—Docetaxel—head and neck cancer	0.000142	0.000792	CcSEcCtD
Bortezomib—Flushing—Docetaxel—head and neck cancer	0.000141	0.000787	CcSEcCtD
Bortezomib—Cardiac disorder—Docetaxel—head and neck cancer	0.000141	0.000787	CcSEcCtD
Bortezomib—Hypotension—Fluorouracil—head and neck cancer	0.00014	0.000779	CcSEcCtD
Bortezomib—Angiopathy—Docetaxel—head and neck cancer	0.000138	0.000769	CcSEcCtD
Bortezomib—Dizziness—Hydroxyurea—head and neck cancer	0.000137	0.000766	CcSEcCtD
Bortezomib—Immune system disorder—Docetaxel—head and neck cancer	0.000137	0.000765	CcSEcCtD
Bortezomib—Mediastinal disorder—Docetaxel—head and neck cancer	0.000137	0.000764	CcSEcCtD
Bortezomib—Chills—Docetaxel—head and neck cancer	0.000136	0.00076	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Fluorouracil—head and neck cancer	0.000136	0.00076	CcSEcCtD
Bortezomib—Arrhythmia—Docetaxel—head and neck cancer	0.000136	0.000757	CcSEcCtD
Bortezomib—Nausea—Vinblastine—head and neck cancer	0.000135	0.000755	CcSEcCtD
Bortezomib—Insomnia—Fluorouracil—head and neck cancer	0.000135	0.000754	CcSEcCtD
Bortezomib—Paraesthesia—Fluorouracil—head and neck cancer	0.000134	0.000749	CcSEcCtD
Bortezomib—Dyspnoea—Fluorouracil—head and neck cancer	0.000133	0.000744	CcSEcCtD
Bortezomib—Mental disorder—Docetaxel—head and neck cancer	0.000133	0.000742	CcSEcCtD
Bortezomib—Malnutrition—Docetaxel—head and neck cancer	0.000132	0.000738	CcSEcCtD
Bortezomib—Erythema—Docetaxel—head and neck cancer	0.000132	0.000738	CcSEcCtD
Bortezomib—Vomiting—Hydroxyurea—head and neck cancer	0.000132	0.000737	CcSEcCtD
Bortezomib—Dyspepsia—Fluorouracil—head and neck cancer	0.000132	0.000734	CcSEcCtD
Bortezomib—Rash—Hydroxyurea—head and neck cancer	0.000131	0.000731	CcSEcCtD
Bortezomib—PTGS1—lymph node—head and neck cancer	0.000131	0.00144	CbGeAlD
Bortezomib—Dermatitis—Hydroxyurea—head and neck cancer	0.000131	0.00073	CcSEcCtD
Bortezomib—Headache—Hydroxyurea—head and neck cancer	0.00013	0.000726	CcSEcCtD
Bortezomib—Decreased appetite—Fluorouracil—head and neck cancer	0.00013	0.000725	CcSEcCtD
Bortezomib—Dysgeusia—Docetaxel—head and neck cancer	0.00013	0.000722	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Fluorouracil—head and neck cancer	0.000129	0.00072	CcSEcCtD
Bortezomib—Back pain—Docetaxel—head and neck cancer	0.000128	0.000714	CcSEcCtD
Bortezomib—Pain—Fluorouracil—head and neck cancer	0.000128	0.000713	CcSEcCtD
Bortezomib—Muscle spasms—Docetaxel—head and neck cancer	0.000127	0.000709	CcSEcCtD
Bortezomib—Nausea—Hydroxyurea—head and neck cancer	0.000123	0.000688	CcSEcCtD
Bortezomib—Feeling abnormal—Fluorouracil—head and neck cancer	0.000123	0.000687	CcSEcCtD
Bortezomib—Anaemia—Docetaxel—head and neck cancer	0.000122	0.000682	CcSEcCtD
Bortezomib—Urticaria—Fluorouracil—head and neck cancer	0.000119	0.000663	CcSEcCtD
Bortezomib—Syncope—Docetaxel—head and neck cancer	0.000119	0.000662	CcSEcCtD
Bortezomib—Leukopenia—Docetaxel—head and neck cancer	0.000118	0.00066	CcSEcCtD
Bortezomib—Body temperature increased—Fluorouracil—head and neck cancer	0.000118	0.000659	CcSEcCtD
Bortezomib—Palpitations—Docetaxel—head and neck cancer	0.000117	0.000652	CcSEcCtD
Bortezomib—Loss of consciousness—Docetaxel—head and neck cancer	0.000116	0.000648	CcSEcCtD
Bortezomib—Cough—Docetaxel—head and neck cancer	0.000115	0.000644	CcSEcCtD
Bortezomib—Convulsion—Docetaxel—head and neck cancer	0.000115	0.000639	CcSEcCtD
Bortezomib—Hypertension—Docetaxel—head and neck cancer	0.000114	0.000637	CcSEcCtD
Bortezomib—Myalgia—Docetaxel—head and neck cancer	0.000113	0.000628	CcSEcCtD
Bortezomib—Chest pain—Docetaxel—head and neck cancer	0.000113	0.000628	CcSEcCtD
Bortezomib—Arthralgia—Docetaxel—head and neck cancer	0.000113	0.000628	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—head and neck cancer	0.000112	0.000624	CcSEcCtD
Bortezomib—Hypersensitivity—Fluorouracil—head and neck cancer	0.00011	0.000615	CcSEcCtD
Bortezomib—Confusional state—Docetaxel—head and neck cancer	0.000109	0.000607	CcSEcCtD
Bortezomib—Oedema—Docetaxel—head and neck cancer	0.000108	0.000602	CcSEcCtD
Bortezomib—Anaphylactic shock—Docetaxel—head and neck cancer	0.000108	0.000602	CcSEcCtD
Bortezomib—Infection—Docetaxel—head and neck cancer	0.000107	0.000598	CcSEcCtD
Bortezomib—Shock—Docetaxel—head and neck cancer	0.000106	0.000592	CcSEcCtD
Bortezomib—Nervous system disorder—Docetaxel—head and neck cancer	0.000106	0.00059	CcSEcCtD
Bortezomib—Pruritus—Fluorouracil—head and neck cancer	0.000106	0.00059	CcSEcCtD
Bortezomib—Thrombocytopenia—Docetaxel—head and neck cancer	0.000106	0.00059	CcSEcCtD
Bortezomib—Tachycardia—Docetaxel—head and neck cancer	0.000105	0.000588	CcSEcCtD
Bortezomib—Skin disorder—Docetaxel—head and neck cancer	0.000105	0.000585	CcSEcCtD
Bortezomib—Anorexia—Docetaxel—head and neck cancer	0.000103	0.000574	CcSEcCtD
Bortezomib—Diarrhoea—Fluorouracil—head and neck cancer	0.000102	0.000571	CcSEcCtD
Bortezomib—Hypotension—Docetaxel—head and neck cancer	0.000101	0.000563	CcSEcCtD
Bortezomib—Dizziness—Fluorouracil—head and neck cancer	9.89e-05	0.000552	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Docetaxel—head and neck cancer	9.84e-05	0.000549	CcSEcCtD
Bortezomib—Insomnia—Docetaxel—head and neck cancer	9.76e-05	0.000545	CcSEcCtD
Bortezomib—Paraesthesia—Docetaxel—head and neck cancer	9.69e-05	0.000541	CcSEcCtD
Bortezomib—Dyspnoea—Docetaxel—head and neck cancer	9.63e-05	0.000537	CcSEcCtD
Bortezomib—Vomiting—Fluorouracil—head and neck cancer	9.51e-05	0.00053	CcSEcCtD
Bortezomib—Dyspepsia—Docetaxel—head and neck cancer	9.5e-05	0.00053	CcSEcCtD
Bortezomib—Rash—Fluorouracil—head and neck cancer	9.43e-05	0.000526	CcSEcCtD
Bortezomib—Dermatitis—Fluorouracil—head and neck cancer	9.42e-05	0.000525	CcSEcCtD
Bortezomib—Decreased appetite—Docetaxel—head and neck cancer	9.39e-05	0.000523	CcSEcCtD
Bortezomib—Headache—Fluorouracil—head and neck cancer	9.37e-05	0.000523	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Docetaxel—head and neck cancer	9.32e-05	0.00052	CcSEcCtD
Bortezomib—Fatigue—Docetaxel—head and neck cancer	9.31e-05	0.000519	CcSEcCtD
Bortezomib—Constipation—Docetaxel—head and neck cancer	9.23e-05	0.000515	CcSEcCtD
Bortezomib—Pain—Docetaxel—head and neck cancer	9.23e-05	0.000515	CcSEcCtD
Bortezomib—Feeling abnormal—Docetaxel—head and neck cancer	8.9e-05	0.000496	CcSEcCtD
Bortezomib—Nausea—Fluorouracil—head and neck cancer	8.89e-05	0.000495	CcSEcCtD
Bortezomib—Gastrointestinal pain—Docetaxel—head and neck cancer	8.83e-05	0.000492	CcSEcCtD
Bortezomib—Abdominal pain—Docetaxel—head and neck cancer	8.53e-05	0.000476	CcSEcCtD
Bortezomib—Body temperature increased—Docetaxel—head and neck cancer	8.53e-05	0.000476	CcSEcCtD
Bortezomib—Hypersensitivity—Docetaxel—head and neck cancer	7.95e-05	0.000444	CcSEcCtD
Bortezomib—Asthenia—Docetaxel—head and neck cancer	7.75e-05	0.000432	CcSEcCtD
Bortezomib—Pruritus—Docetaxel—head and neck cancer	7.64e-05	0.000426	CcSEcCtD
Bortezomib—Diarrhoea—Docetaxel—head and neck cancer	7.39e-05	0.000412	CcSEcCtD
Bortezomib—Dizziness—Docetaxel—head and neck cancer	7.14e-05	0.000398	CcSEcCtD
Bortezomib—Vomiting—Docetaxel—head and neck cancer	6.86e-05	0.000383	CcSEcCtD
Bortezomib—Rash—Docetaxel—head and neck cancer	6.81e-05	0.00038	CcSEcCtD
Bortezomib—Dermatitis—Docetaxel—head and neck cancer	6.8e-05	0.000379	CcSEcCtD
Bortezomib—Headache—Docetaxel—head and neck cancer	6.76e-05	0.000377	CcSEcCtD
Bortezomib—Nausea—Docetaxel—head and neck cancer	6.41e-05	0.000358	CcSEcCtD
Bortezomib—PSMB8—Gene Expression—MAPK3—head and neck cancer	1.42e-05	9.38e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—TYMS—head and neck cancer	1.41e-05	9.31e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—STAT3—head and neck cancer	1.4e-05	9.24e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—STAT3—head and neck cancer	1.4e-05	9.24e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—STAT3—head and neck cancer	1.4e-05	9.24e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—GSTM1—head and neck cancer	1.39e-05	9.2e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—STAT3—head and neck cancer	1.38e-05	9.11e-05	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—MAPK1—head and neck cancer	1.38e-05	9.1e-05	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—MAPK1—head and neck cancer	1.38e-05	9.1e-05	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—MAPK1—head and neck cancer	1.38e-05	9.1e-05	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—EGFR—head and neck cancer	1.38e-05	9.1e-05	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—EGFR—head and neck cancer	1.38e-05	9.1e-05	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—EGFR—head and neck cancer	1.38e-05	9.1e-05	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—MAPK1—head and neck cancer	1.36e-05	8.97e-05	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—EGFR—head and neck cancer	1.36e-05	8.97e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—YAP1—head and neck cancer	1.35e-05	8.94e-05	CbGpPWpGaD
Bortezomib—PSMA1—Disease—HRAS—head and neck cancer	1.35e-05	8.9e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	1.35e-05	8.89e-05	CbGpPWpGaD
Bortezomib—PSMD1—Disease—HRAS—head and neck cancer	1.34e-05	8.86e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—MAPK3—head and neck cancer	1.34e-05	8.83e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—MAPK3—head and neck cancer	1.34e-05	8.83e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—MAPK3—head and neck cancer	1.34e-05	8.83e-05	CbGpPWpGaD
Bortezomib—PSMD2—Disease—HRAS—head and neck cancer	1.34e-05	8.82e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—GPX1—head and neck cancer	1.34e-05	8.81e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	1.33e-05	8.8e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—CYP1A1—head and neck cancer	1.32e-05	8.73e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—MAPK3—head and neck cancer	1.32e-05	8.71e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—DPYD—head and neck cancer	1.31e-05	8.67e-05	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—PTEN—head and neck cancer	1.31e-05	8.66e-05	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—PTEN—head and neck cancer	1.31e-05	8.66e-05	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—PTEN—head and neck cancer	1.31e-05	8.66e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—VEGFA—head and neck cancer	1.31e-05	8.63e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—DPYD—head and neck cancer	1.3e-05	8.59e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—VEGFA—head and neck cancer	1.3e-05	8.59e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—VEGFA—head and neck cancer	1.29e-05	8.54e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—STAT3—head and neck cancer	1.29e-05	8.54e-05	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—PTEN—head and neck cancer	1.29e-05	8.53e-05	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—AKT1—head and neck cancer	1.29e-05	8.51e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—STAT3—head and neck cancer	1.29e-05	8.5e-05	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—AKT1—head and neck cancer	1.28e-05	8.47e-05	CbGpPWpGaD
Bortezomib—PSMA1—Gene Expression—AKT1—head and neck cancer	1.28e-05	8.47e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—STAT3—head and neck cancer	1.28e-05	8.46e-05	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—AKT1—head and neck cancer	1.28e-05	8.43e-05	CbGpPWpGaD
Bortezomib—PSMD1—Gene Expression—AKT1—head and neck cancer	1.28e-05	8.43e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—MAPK1—head and neck cancer	1.27e-05	8.4e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—MAPK1—head and neck cancer	1.27e-05	8.4e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—MAPK1—head and neck cancer	1.27e-05	8.4e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—EGFR—head and neck cancer	1.27e-05	8.4e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—EGFR—head and neck cancer	1.27e-05	8.4e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—EGFR—head and neck cancer	1.27e-05	8.4e-05	CbGpPWpGaD
Bortezomib—PSMD2—Gene Expression—AKT1—head and neck cancer	1.27e-05	8.39e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—NAT2—head and neck cancer	1.27e-05	8.37e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—MAPK1—head and neck cancer	1.26e-05	8.28e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—EGFR—head and neck cancer	1.25e-05	8.28e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—YAP1—head and neck cancer	1.25e-05	8.22e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	1.24e-05	8.21e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—MAPK3—head and neck cancer	1.24e-05	8.16e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—YAP1—head and neck cancer	1.24e-05	8.15e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—MAPK3—head and neck cancer	1.23e-05	8.12e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—MAPK3—head and neck cancer	1.22e-05	8.08e-05	CbGpPWpGaD
Bortezomib—PSMA1—Metabolism—PIK3CA—head and neck cancer	1.22e-05	8.06e-05	CbGpPWpGaD
Bortezomib—PSMD1—Metabolism—PIK3CA—head and neck cancer	1.21e-05	8.02e-05	CbGpPWpGaD
Bortezomib—PSMD2—Metabolism—PIK3CA—head and neck cancer	1.21e-05	7.98e-05	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—PIK3CA—head and neck cancer	1.2e-05	7.9e-05	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—PIK3CA—head and neck cancer	1.2e-05	7.9e-05	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—PIK3CA—head and neck cancer	1.2e-05	7.9e-05	CbGpPWpGaD
Bortezomib—PSMA1—Disease—AKT1—head and neck cancer	1.19e-05	7.86e-05	CbGpPWpGaD
Bortezomib—PSMD1—Disease—AKT1—head and neck cancer	1.19e-05	7.82e-05	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—PIK3CA—head and neck cancer	1.18e-05	7.79e-05	CbGpPWpGaD
Bortezomib—PSMD2—Disease—AKT1—head and neck cancer	1.18e-05	7.79e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—MAPK1—head and neck cancer	1.18e-05	7.76e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—EGFR—head and neck cancer	1.18e-05	7.76e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—MAPK1—head and neck cancer	1.17e-05	7.73e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—EGFR—head and neck cancer	1.17e-05	7.73e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—IL2—head and neck cancer	1.17e-05	7.69e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—IL2—head and neck cancer	1.17e-05	7.69e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—IL2—head and neck cancer	1.17e-05	7.69e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—MAPK1—head and neck cancer	1.17e-05	7.69e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—EGFR—head and neck cancer	1.16e-05	7.69e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—IL2—head and neck cancer	1.15e-05	7.58e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	1.14e-05	7.53e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—CCND1—head and neck cancer	1.14e-05	7.5e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—CCND1—head and neck cancer	1.14e-05	7.5e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—CCND1—head and neck cancer	1.14e-05	7.5e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—CCND1—head and neck cancer	1.12e-05	7.39e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—DPYD—head and neck cancer	1.11e-05	7.34e-05	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—HRAS—head and neck cancer	1.11e-05	7.31e-05	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—HRAS—head and neck cancer	1.11e-05	7.31e-05	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—HRAS—head and neck cancer	1.11e-05	7.31e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—PIK3CA—head and neck cancer	1.1e-05	7.29e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—PIK3CA—head and neck cancer	1.1e-05	7.29e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—PIK3CA—head and neck cancer	1.1e-05	7.29e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—PTEN—head and neck cancer	1.1e-05	7.24e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—PTEN—head and neck cancer	1.1e-05	7.24e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—PTEN—head and neck cancer	1.1e-05	7.24e-05	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—HRAS—head and neck cancer	1.09e-05	7.2e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—PIK3CA—head and neck cancer	1.09e-05	7.19e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	1.09e-05	7.17e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	1.08e-05	7.16e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—PTEN—head and neck cancer	1.08e-05	7.14e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—YAP1—head and neck cancer	1.06e-05	6.97e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—HRAS—head and neck cancer	1.02e-05	6.75e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—HRAS—head and neck cancer	1.02e-05	6.75e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—HRAS—head and neck cancer	1.02e-05	6.75e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—PIK3CA—head and neck cancer	1.02e-05	6.74e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	1.02e-05	6.72e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—PIK3CA—head and neck cancer	1.02e-05	6.71e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—PIK3CA—head and neck cancer	1.01e-05	6.67e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—HRAS—head and neck cancer	1.01e-05	6.65e-05	CbGpPWpGaD
Bortezomib—PSMA1—Metabolism—AKT1—head and neck cancer	9.97e-06	6.58e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	9.94e-06	6.56e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—TYMS—head and neck cancer	9.94e-06	6.56e-05	CbGpPWpGaD
Bortezomib—PSMD1—Metabolism—AKT1—head and neck cancer	9.92e-06	6.55e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—VEGFA—head and neck cancer	9.9e-06	6.54e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—VEGFA—head and neck cancer	9.9e-06	6.54e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—VEGFA—head and neck cancer	9.9e-06	6.54e-05	CbGpPWpGaD
Bortezomib—PSMD2—Metabolism—AKT1—head and neck cancer	9.88e-06	6.52e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—TP53—head and neck cancer	9.87e-06	6.52e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—TP53—head and neck cancer	9.83e-06	6.49e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—GSTM1—head and neck cancer	9.82e-06	6.49e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—STAT3—head and neck cancer	9.81e-06	6.47e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—STAT3—head and neck cancer	9.81e-06	6.47e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—STAT3—head and neck cancer	9.81e-06	6.47e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—NAT2—head and neck cancer	9.79e-06	6.46e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—TP53—head and neck cancer	9.78e-06	6.46e-05	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—AKT1—head and neck cancer	9.77e-06	6.45e-05	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—AKT1—head and neck cancer	9.77e-06	6.45e-05	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—AKT1—head and neck cancer	9.77e-06	6.45e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—VEGFA—head and neck cancer	9.76e-06	6.45e-05	CbGpPWpGaD
Bortezomib—PSMB1—Gene Expression—AKT1—head and neck cancer	9.72e-06	6.42e-05	CbGpPWpGaD
Bortezomib—PSMB2—Gene Expression—AKT1—head and neck cancer	9.72e-06	6.42e-05	CbGpPWpGaD
Bortezomib—PSMB5—Gene Expression—AKT1—head and neck cancer	9.72e-06	6.42e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—STAT3—head and neck cancer	9.67e-06	6.38e-05	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—AKT1—head and neck cancer	9.64e-06	6.36e-05	CbGpPWpGaD
Bortezomib—PSMB8—Gene Expression—AKT1—head and neck cancer	9.58e-06	6.33e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—HRAS—head and neck cancer	9.44e-06	6.23e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—GPX1—head and neck cancer	9.41e-06	6.21e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—HRAS—head and neck cancer	9.4e-06	6.2e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—MAPK3—head and neck cancer	9.37e-06	6.18e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—MAPK3—head and neck cancer	9.37e-06	6.18e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—MAPK3—head and neck cancer	9.37e-06	6.18e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—HRAS—head and neck cancer	9.35e-06	6.17e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	9.28e-06	6.13e-05	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—PIK3CA—head and neck cancer	9.25e-06	6.11e-05	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—PIK3CA—head and neck cancer	9.25e-06	6.11e-05	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—PIK3CA—head and neck cancer	9.25e-06	6.11e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—MAPK3—head and neck cancer	9.24e-06	6.1e-05	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—PIK3CA—head and neck cancer	9.12e-06	6.02e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—TYMS—head and neck cancer	9.11e-06	6.01e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—AKT1—head and neck cancer	9.02e-06	5.96e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—AKT1—head and neck cancer	9.02e-06	5.96e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—AKT1—head and neck cancer	9.02e-06	5.96e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—GSTM1—head and neck cancer	9.01e-06	5.95e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—MAPK1—head and neck cancer	8.91e-06	5.88e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—MAPK1—head and neck cancer	8.91e-06	5.88e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—MAPK1—head and neck cancer	8.91e-06	5.88e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—EGFR—head and neck cancer	8.91e-06	5.88e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—EGFR—head and neck cancer	8.91e-06	5.88e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—EGFR—head and neck cancer	8.91e-06	5.88e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—AKT1—head and neck cancer	8.9e-06	5.87e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	8.88e-06	5.86e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—MAPK1—head and neck cancer	8.79e-06	5.8e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—EGFR—head and neck cancer	8.79e-06	5.8e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—GPX1—head and neck cancer	8.63e-06	5.69e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—DPYD—head and neck cancer	8.58e-06	5.67e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—CYP1A1—head and neck cancer	8.54e-06	5.64e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—AKT1—head and neck cancer	8.34e-06	5.5e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—AKT1—head and neck cancer	8.3e-06	5.48e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—AKT1—head and neck cancer	8.26e-06	5.45e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—YAP1—head and neck cancer	8.15e-06	5.38e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—TYMS—head and neck cancer	8.13e-06	5.37e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	8.09e-06	5.34e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—GSTM1—head and neck cancer	8.04e-06	5.31e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	7.93e-06	5.23e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PTGS2—head and neck cancer	7.86e-06	5.19e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—PIK3CA—head and neck cancer	7.74e-06	5.11e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—PIK3CA—head and neck cancer	7.74e-06	5.11e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—PIK3CA—head and neck cancer	7.74e-06	5.11e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—GPX1—head and neck cancer	7.7e-06	5.08e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	7.65e-06	5.05e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—PIK3CA—head and neck cancer	7.63e-06	5.03e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—CYP1A1—head and neck cancer	7.62e-06	5.03e-05	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—AKT1—head and neck cancer	7.56e-06	4.99e-05	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—AKT1—head and neck cancer	7.56e-06	4.99e-05	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—AKT1—head and neck cancer	7.56e-06	4.99e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—TP53—head and neck cancer	7.48e-06	4.94e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—TP53—head and neck cancer	7.48e-06	4.94e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—TP53—head and neck cancer	7.48e-06	4.94e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—TYMS—head and neck cancer	7.48e-06	4.94e-05	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—AKT1—head and neck cancer	7.45e-06	4.92e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—TYMS—head and neck cancer	7.42e-06	4.9e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—GSTM1—head and neck cancer	7.39e-06	4.88e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—TP53—head and neck cancer	7.38e-06	4.87e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—GSTM1—head and neck cancer	7.33e-06	4.84e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—HRAS—head and neck cancer	7.16e-06	4.72e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—HRAS—head and neck cancer	7.16e-06	4.72e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—HRAS—head and neck cancer	7.16e-06	4.72e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—GPX1—head and neck cancer	7.08e-06	4.67e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—HRAS—head and neck cancer	7.06e-06	4.66e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—GPX1—head and neck cancer	7.02e-06	4.63e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	7.01e-06	4.63e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—CYP1A1—head and neck cancer	7.01e-06	4.63e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—CYP1A1—head and neck cancer	6.95e-06	4.59e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	6.92e-06	4.56e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PTEN—head and neck cancer	6.86e-06	4.53e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—TYMS—head and neck cancer	6.34e-06	4.18e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—AKT1—head and neck cancer	6.32e-06	4.17e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—AKT1—head and neck cancer	6.32e-06	4.17e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—AKT1—head and neck cancer	6.32e-06	4.17e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—GSTM1—head and neck cancer	6.26e-06	4.14e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	6.26e-06	4.13e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—AKT1—head and neck cancer	6.23e-06	4.11e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—GPX1—head and neck cancer	6e-06	3.96e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—CYP1A1—head and neck cancer	5.94e-06	3.92e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	5.71e-06	3.77e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PTGS2—head and neck cancer	5.54e-06	3.66e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PTGS2—head and neck cancer	5.08e-06	3.35e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—TYMS—head and neck cancer	4.89e-06	3.23e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	4.88e-06	3.22e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PIK3CA—head and neck cancer	4.84e-06	3.19e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GSTM1—head and neck cancer	4.83e-06	3.19e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PTEN—head and neck cancer	4.83e-06	3.19e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GPX1—head and neck cancer	4.63e-06	3.06e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CYP1A1—head and neck cancer	4.58e-06	3.03e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PTGS2—head and neck cancer	4.53e-06	2.99e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PTEN—head and neck cancer	4.43e-06	2.92e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PTGS2—head and neck cancer	4.17e-06	2.75e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PTGS2—head and neck cancer	4.13e-06	2.73e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PTEN—head and neck cancer	3.95e-06	2.61e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—AKT1—head and neck cancer	3.95e-06	2.61e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PTEN—head and neck cancer	3.64e-06	2.4e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PTEN—head and neck cancer	3.6e-06	2.38e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PTGS2—head and neck cancer	3.53e-06	2.33e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PIK3CA—head and neck cancer	3.41e-06	2.25e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PIK3CA—head and neck cancer	3.12e-06	2.06e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PTEN—head and neck cancer	3.08e-06	2.03e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PIK3CA—head and neck cancer	2.79e-06	1.84e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—AKT1—head and neck cancer	2.78e-06	1.84e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PTGS2—head and neck cancer	2.73e-06	1.8e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PIK3CA—head and neck cancer	2.56e-06	1.69e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—AKT1—head and neck cancer	2.55e-06	1.68e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PIK3CA—head and neck cancer	2.54e-06	1.68e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PTEN—head and neck cancer	2.38e-06	1.57e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—AKT1—head and neck cancer	2.28e-06	1.5e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PIK3CA—head and neck cancer	2.17e-06	1.43e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—AKT1—head and neck cancer	2.1e-06	1.38e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—AKT1—head and neck cancer	2.08e-06	1.37e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—AKT1—head and neck cancer	1.77e-06	1.17e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PIK3CA—head and neck cancer	1.68e-06	1.11e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—AKT1—head and neck cancer	1.37e-06	9.04e-06	CbGpPWpGaD
